This brand name is authorized in Turkey
The drug SEFOTAK contains a combination of these active pharmaceutical ingredients (APIs):
|
1
Cefotaxime
UNII 258J72S7TZ - CEFOTAXIME SODIUM
|
|
Cefotaxime exerts its action by binding to one or more of the penicillin-binding proteins (PBPs) which in turn inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell walls, thereby inhibiting cell wall synthesis. |
|
2
Lidocaine
UNII V13007Z41A - LIDOCAINE HYDROCHLORIDE
|
|
Lidocaine, like other local anaesthetics, causes a reversible blockade of impulse propagation along nerve fibres by preventing the inward movement of sodium ions through the nerve membrane. Local anaesthetics of the amide-type are thought to act within the sodium channels of the nerve membrane. |
This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:
| ATC code | Group title | Classification |
|---|---|---|
| J01DD01 | Cefotaxime | J Antiinfectives for systemic use → J01 Antibacterials for systemic use → J01D Other beta-lactam antibacterials → J01DD Third-generation cephalosporins |
This drug has been assigned below unique identifiers within the countries it is being marketed:
| Country | Identification scheme | Identifier(s) |
|---|---|---|
| Country: TR | ฤฐlaรง ve Tฤฑbbi Cihaz Kurumu | Identifier(s): 8699502270541 |
ยฉ All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
